Cargando…
Biologic Treatments of Psoriasis: An Update for the Clinician
The advent of biologic agents within the past two decades has dramatically improved the treatment of psoriasis and psoriatic arthritis. Given that there now exists 11 FDA approved biologic options available for psoriasis, with more in the pipeline, the therapeutic armamentarium has been greatly enha...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7896737/ https://www.ncbi.nlm.nih.gov/pubmed/33623366 http://dx.doi.org/10.2147/BTT.S252578 |
_version_ | 1783653600269959168 |
---|---|
author | Brownstone, Nicholas D Hong, Julie Mosca, Megan Hadeler, Edward Liao, Wilson Bhutani, Tina Koo, John |
author_facet | Brownstone, Nicholas D Hong, Julie Mosca, Megan Hadeler, Edward Liao, Wilson Bhutani, Tina Koo, John |
author_sort | Brownstone, Nicholas D |
collection | PubMed |
description | The advent of biologic agents within the past two decades has dramatically improved the treatment of psoriasis and psoriatic arthritis. Given that there now exists 11 FDA approved biologic options available for psoriasis, with more in the pipeline, the therapeutic armamentarium has been greatly enhanced. However, the fact that there are so many available options has also caused confusion for providers. Therefore, this manuscript deliberately focuses on the most clinically useful facts (such as efficacy and safety data) about each and every FDA approved biologic agent (including pipeline agents) for psoriasis. Moreover, among the clinically relevant facts, this manuscript purposely emphasizes the unique merits and demerits of each agent to make it easier for the provider to select which one of these many options is the best for the particular patient on hand. The goal of this manuscript is to aid the busy practicing dermatologist in becoming more adept at using these agents with the ultimate aim of improving patient care. |
format | Online Article Text |
id | pubmed-7896737 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-78967372021-02-22 Biologic Treatments of Psoriasis: An Update for the Clinician Brownstone, Nicholas D Hong, Julie Mosca, Megan Hadeler, Edward Liao, Wilson Bhutani, Tina Koo, John Biologics Review The advent of biologic agents within the past two decades has dramatically improved the treatment of psoriasis and psoriatic arthritis. Given that there now exists 11 FDA approved biologic options available for psoriasis, with more in the pipeline, the therapeutic armamentarium has been greatly enhanced. However, the fact that there are so many available options has also caused confusion for providers. Therefore, this manuscript deliberately focuses on the most clinically useful facts (such as efficacy and safety data) about each and every FDA approved biologic agent (including pipeline agents) for psoriasis. Moreover, among the clinically relevant facts, this manuscript purposely emphasizes the unique merits and demerits of each agent to make it easier for the provider to select which one of these many options is the best for the particular patient on hand. The goal of this manuscript is to aid the busy practicing dermatologist in becoming more adept at using these agents with the ultimate aim of improving patient care. Dove 2021-02-16 /pmc/articles/PMC7896737/ /pubmed/33623366 http://dx.doi.org/10.2147/BTT.S252578 Text en © 2021 Brownstone et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Review Brownstone, Nicholas D Hong, Julie Mosca, Megan Hadeler, Edward Liao, Wilson Bhutani, Tina Koo, John Biologic Treatments of Psoriasis: An Update for the Clinician |
title | Biologic Treatments of Psoriasis: An Update for the Clinician |
title_full | Biologic Treatments of Psoriasis: An Update for the Clinician |
title_fullStr | Biologic Treatments of Psoriasis: An Update for the Clinician |
title_full_unstemmed | Biologic Treatments of Psoriasis: An Update for the Clinician |
title_short | Biologic Treatments of Psoriasis: An Update for the Clinician |
title_sort | biologic treatments of psoriasis: an update for the clinician |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7896737/ https://www.ncbi.nlm.nih.gov/pubmed/33623366 http://dx.doi.org/10.2147/BTT.S252578 |
work_keys_str_mv | AT brownstonenicholasd biologictreatmentsofpsoriasisanupdatefortheclinician AT hongjulie biologictreatmentsofpsoriasisanupdatefortheclinician AT moscamegan biologictreatmentsofpsoriasisanupdatefortheclinician AT hadeleredward biologictreatmentsofpsoriasisanupdatefortheclinician AT liaowilson biologictreatmentsofpsoriasisanupdatefortheclinician AT bhutanitina biologictreatmentsofpsoriasisanupdatefortheclinician AT koojohn biologictreatmentsofpsoriasisanupdatefortheclinician |